Structural Proteomics Offers Keys to Accelerating Pharmaceutical R&D, According to Cambridge Healthtech Institute Report

Apr 17, 2001, 01:00 ET from Cambridge Healthtech Institute

    NEWTON UPPER FALLS, Mass., April 17 /PRNewswire/ -- Structural proteomics
 has emerged as one of the most immediately applicable tools for drug discovery
 and development, according to a new report from Cambridge Healthtech Institute
 (CHI).
     "The field has expanded rapidly and now offers new tools and data to
 improve and accelerate the selection of current drug leads," explains Malorye
 Branca, co-author of the report, titled Structural Proteomics: High-Throughput
 Approaches Fuel Drug Discovery and Development. "It also offers tools for
 quickly identifying the most valuable drug targets from genomics." These
 approaches include protein function prediction, advanced docking tools, biased
 libraries, site-directed NMR (nuclear magnetic resonance), and high-throughput
 structure determination.  "Companies such as Abbott, Novartis, Pfizer,
 Structural GenomiX, Syrrx, and Vertex are taking advantage of these
 capabilities," Ms. Branca adds.
     These companies' and others' strategies in structural proteomics are
 described in this latest publication from CHI, the leading provider of
 information about the business and technology of genomics and proteomics.
 Until April 30, the report's release date, the print version of this title is
 available at a prepublication discount price of $300.
     The report is based on interviews with 14 expert Editorial Advisory Board
 members and thought leaders and contains commentaries by 12 of these
 specialists. It synthesizes hundreds of hours of primary research and also
 contains proprietary data from CHI's Drug Discovery and Development Deals and
 Emerging Companies databases. In addition, the report provides comprehensive
 coverage of companies' structural-proteomics-related activities, profiles key
 competitors, and highlights scientific and business hurdles as well as
 opportunities.
     All activities directly related to structural proteomics -- including
 X-ray crystallography, NMR, and modeling or predictive methods -- are
 described with a level of detail valuable to both experts and nonspecialists.
 Other technologies (e.g., protein expression and purification, screening and
 docking software) that will support or benefit from accelerated structure
 determination are also discussed.
     Clients describe CHI's reports as "great time-savers," "well-focused,"
 "comprehensive," and containing the "highest-caliber" analysis available.
     For more information, including tables of contents, visit CHI's
 publications and online services Web site at www.chireports.com, or contact
 Deborah Brooks at 617-630-1312 or at dbrooks@healthtech.com.  For information
 about CHI's renowned conferences, visit www.healthtech.com.
 
 

SOURCE Cambridge Healthtech Institute
    NEWTON UPPER FALLS, Mass., April 17 /PRNewswire/ -- Structural proteomics
 has emerged as one of the most immediately applicable tools for drug discovery
 and development, according to a new report from Cambridge Healthtech Institute
 (CHI).
     "The field has expanded rapidly and now offers new tools and data to
 improve and accelerate the selection of current drug leads," explains Malorye
 Branca, co-author of the report, titled Structural Proteomics: High-Throughput
 Approaches Fuel Drug Discovery and Development. "It also offers tools for
 quickly identifying the most valuable drug targets from genomics." These
 approaches include protein function prediction, advanced docking tools, biased
 libraries, site-directed NMR (nuclear magnetic resonance), and high-throughput
 structure determination.  "Companies such as Abbott, Novartis, Pfizer,
 Structural GenomiX, Syrrx, and Vertex are taking advantage of these
 capabilities," Ms. Branca adds.
     These companies' and others' strategies in structural proteomics are
 described in this latest publication from CHI, the leading provider of
 information about the business and technology of genomics and proteomics.
 Until April 30, the report's release date, the print version of this title is
 available at a prepublication discount price of $300.
     The report is based on interviews with 14 expert Editorial Advisory Board
 members and thought leaders and contains commentaries by 12 of these
 specialists. It synthesizes hundreds of hours of primary research and also
 contains proprietary data from CHI's Drug Discovery and Development Deals and
 Emerging Companies databases. In addition, the report provides comprehensive
 coverage of companies' structural-proteomics-related activities, profiles key
 competitors, and highlights scientific and business hurdles as well as
 opportunities.
     All activities directly related to structural proteomics -- including
 X-ray crystallography, NMR, and modeling or predictive methods -- are
 described with a level of detail valuable to both experts and nonspecialists.
 Other technologies (e.g., protein expression and purification, screening and
 docking software) that will support or benefit from accelerated structure
 determination are also discussed.
     Clients describe CHI's reports as "great time-savers," "well-focused,"
 "comprehensive," and containing the "highest-caliber" analysis available.
     For more information, including tables of contents, visit CHI's
 publications and online services Web site at www.chireports.com, or contact
 Deborah Brooks at 617-630-1312 or at dbrooks@healthtech.com.  For information
 about CHI's renowned conferences, visit www.healthtech.com.
 
 SOURCE  Cambridge Healthtech Institute